Navigation Links
MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
Date:9/10/2013

nd effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
3. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
4. Pharmaceutical Giants Back Researchers in Unique US Competition
5. Several Market Access Drivers Provide Attractive Opportunities for Multinational Companies in Saudi Arabias Pharmaceutical Market
6. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
7. Sunshine Act 2013 Updates: A Checklist for Pharmaceutical Companies to Meet CMS Reporting
8. PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
9. Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
10. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
11. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  QB3@953—a San ... University of California (UC) research institute and biotech ... GSK to identify and facilitate collaborations to translate ... patients. The agreement formalizes a relationship ... (DPAc) team and creates a new channel for ...
(Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... Chief Executive Officer, will present a corporate overview and business ... New York City . , 22 ... 11:30 am ET at the Millennium Broadway Hotel. , ... pm ET at the St. Regis Hotel. To ...
(Date:8/26/2015)... , Aug. 26, 2015 The North ... witness a CAGR of 7.8% during the forecast period, ... ophthalmology cataract surgery devices market in 2014 and accounted ... ophthalmology cataract surgery devices market is expected to witness ... the increasing strategic expansion of the companies and continuous ...
Breaking Medicine Technology:QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2SciClone To Present At Two Investor Conferences On September 10, 2015 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 3
... 14 Solta Medical, Inc. (Nasdaq: SLTM ), the pioneer ... announced it has received FDA 510(k) clearance for the new ... Fraxel re:store Dual system takes the industry leading ... 1927 nm wavelength, the first ever application of a Thulium laser ...
... 14 Par Pharmaceutical Companies, Inc. (NYSE: PRX ) ... tender offer for a portion of its outstanding 2.875% Senior ... "Modified Dutch Auction" procedure, Par is offering to purchase, for ... up to approximately 82.7%, of the outstanding convertible notes, at ...
Cached Medicine Technology:Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 2Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 2Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 4
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a leading provider ... content is ICD-10 ready and available to all clients. All Krames Patient Education ... which are more targeted and return a more comprehensive data set of content ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... its partnership with Julia Glushko, professional Tennis player for Israel in the Women’s ... Zensah® Compression for all her training and recovery. , With a focus on ...
(Date:8/27/2015)... ... 2015 , ... In addition to its existing Doctor of Philosophy in Leadership ... at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor ... practice nurses for the highest level of clinical nursing practice. , “Our vision ...
(Date:8/27/2015)... GREENWICH, CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract ... agreement to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... -- A new research study conducted by an international team ... including evidence-based guidelines for lower-risk use - to reduce the ... Led by CAMH scientist and CIHR/PHAC* Chair in Applied ... study is being published in the September/October 2011 issue of ...
... of medicines commonly given for pain -- were associated with ... adults, aged 65 to 94, e-published in advance of publication ... The study from researchers at Group Health Research Institute and ... are drugs generally given for insomnia and anxiety, did not ...
... , THURSDAY, Sept. 22 (HealthDay News) -- There ... and other recreational water in the United States in ... to two federal reports released Thursday. The 134 ... and December 2008 occurred in 38 states and Puerto ...
... HealthDay Reporter , THURSDAY, Sept. 22 (HealthDay News) -- ... prostate biopsy are hospitalized within 30 days of the procedure, ... of similarly aged men who do not get prostate biopsies can ... issue of the Journal of Urology . "The overall ...
... By Steven Reinberg HealthDay Reporter , ... containing chloroflouorocarbons (CFCs), which can damage the ozone layer, ... the U.S. Food and Drug Administration announced Thursday. ... Armstrong Pharmaceutical Inc., because it is the only inhaler ...
... of Kentucky,s Dr. Susanne Arnold and colleagues were awarded a ... reasons for the high lung cancer rates in Eastern Kentucky. ... the study began on Sept. 15. Kentucky has the ... the southeastern portion of the state those in the ...
Cached Medicine News:Health News:New study proposes public health guidelines to reduce the harms from cannabis use 2Health News:New study proposes public health guidelines to reduce the harms from cannabis use 3Health News:Opioids linked to higher risk of pneumonia in older adults 2Health News:Infections Linked to Swimming, Drinking Water: CDC 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 3Health News:Asthma Inhaler Primatene Mist Going Off the Market 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 3
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... The Blue Line UNO Splint fits small, medium, ... cushioned two-part design includes both dorsal and volar ... extension. Recommended for those experiencing symptoms of Carpal ... for busy clinics - stock one splint to ...
Comfort Wrist Immobilizer with thumb abduction. 8"L, soft, padded comfort-type wrist immobilizer with dorsal metal stay. The thumb is held in abduction and splintered with a short metal stay....
Medicine Products: